hydroxyurea has been researched along with Recrudescence in 62 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 9.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported." | 9.07 | Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. ( Bundy, BN; Creasman, WT; d'Ablaing, G; Fowler, WC; Keys, HM; Mortel, R; Stehman, FB; Thomas, G, 1993) |
| "We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 7.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
| "We report on three patients who developed fever after starting treatment with the anti-neoplastic agent, hydroxyurea." | 7.69 | Fever attributed to the use of hydroxyurea. ( Feenstra, J; in 't Veld, BA; Runhaar, EA; Slappendel, AM; Stricker, BH; van Aken, J; Veen, C, 1997) |
| "Hydroxyurea has been rarely implicated as a cause of drug fever." | 7.66 | Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981) |
| "The standard care protocol requires that children with acute strokes be treated with hydroxyurea at a fixed dose of 20 mg/kg/day within two months of the stroke." | 5.30 | Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial. ( Abdullahi, SU; DeBaun, MR; Galadanci, NA; Jordan, LC; Rodeghier, M, 2019) |
| "Drug-induced fever is a frequent (3-5% of all adverse effects) but under recognized adverse effect of several drugs." | 5.30 | [Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases]. ( Allochon, Y; Blanc, M; Evreux, JC; Gallant, C; Monier, JM; Vial, T, 1998) |
| "A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 micrograms/kg i." | 5.28 | Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. ( Archimbaud, E; Devaux, Y; Fiere, D; French, M; Guyotat, D; Moriceau, M; Sebban, C; Troncy, J; Viala, JJ, 1989) |
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 5.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported." | 5.07 | Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. ( Bundy, BN; Creasman, WT; d'Ablaing, G; Fowler, WC; Keys, HM; Mortel, R; Stehman, FB; Thomas, G, 1993) |
| "We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 3.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
| "We report on three patients who developed fever after starting treatment with the anti-neoplastic agent, hydroxyurea." | 3.69 | Fever attributed to the use of hydroxyurea. ( Feenstra, J; in 't Veld, BA; Runhaar, EA; Slappendel, AM; Stricker, BH; van Aken, J; Veen, C, 1997) |
| "Hydroxyurea has been rarely implicated as a cause of drug fever." | 3.66 | Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981) |
| "Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "BACKGROUND Priapism is rarely reported as a complication in patients with essential thrombocythemia at presentation." | 2.66 | Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature. ( Jain, M; Kumar, N; Tripathi, AK; Verma, SP, 2020) |
| "Patients with hyperleukocytic (HL) acute myeloid leukemia (AML) are at higher risk of early death." | 1.72 | Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. ( Adès, L; Azoulay, E; Boissel, N; Chevret, S; Fodil, S; Itzykson, R; Lengliné, E; Mariotte, E; Rabian, F; Raffoux, E; Rouzaud, C; Sébert, M; Valade, S; Zafrani, L, 2022) |
| "Polycythemia is a rare but important preventable cause of stroke with potential for recurrence when not identified and appropriately managed." | 1.51 | Recurrent Stroke in a Ghanaian Patient With Polycythemia. ( Berchie, PO; Opare-Sem, OK; Ovbiagele, B; Sarfo, FS, 2019) |
| " Optimal therapeutic dosing and adherence to HC treatment significantly reduces 30-day readmissions among patients with SCD." | 1.48 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. ( Calip, GS; Gordeuk, VR; Han, J; Nutescu, EA; Saraf, SL; Zhou, J, 2018) |
| "We recorded 348 recurrences (venous in 142 cases) over 6075 patient-years, with an incidence rate of 5." | 1.48 | Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. ( Barbui, T; Betti, S; Carobbio, A; De Stefano, V; Finazzi, G; Ghirardi, A; Rossi, E; Vannucchi, AM, 2018) |
| " We observed that long-term maintenance with hydroxyurea at a dosage of 15 mg/kg every 48 hours was adequate for managing polycythemia vera, with a survival time of 18 months in the present case." | 1.42 | Diagnosis and Treatment of Primary Erythrocytosis in a Dog: A Case Report. ( Arias, MV; Bonelli, Mde A; Camassa, JA; Diogo, CC; Fabretti, AK; Pereira, PM, 2015) |
| "We report on a patient with a cerebral infarction affecting the right lateral thalamus and a stenotic lesion of the right posterior cerebral artery." | 1.38 | Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia. ( Cho, KH; Kim, KT; Sohn, SI, 2012) |
| "Hydroxyurea treatment, as well as and long- and short-acting narcotics were given, with little improvement in symptoms." | 1.33 | Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. ( Abish, S; Albuquerque, P; Alyaarubi, S; Gale, M; Jabado, N; Krishnamoorthy, P, 2006) |
| "Only one report of recurrence of myocardial infarction has been previously described." | 1.31 | Essential thrombocythemia and recurrent myocardial infarction. ( Akarsu, E; Bozkurt, E; Gündogdu, M; Kaya, H; Tekin, SB, 2000) |
| "Drug-induced fever is a frequent (3-5% of all adverse effects) but under recognized adverse effect of several drugs." | 1.30 | [Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases]. ( Allochon, Y; Blanc, M; Evreux, JC; Gallant, C; Monier, JM; Vial, T, 1998) |
| "A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 micrograms/kg i." | 1.28 | Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. ( Archimbaud, E; Devaux, Y; Fiere, D; French, M; Guyotat, D; Moriceau, M; Sebban, C; Troncy, J; Viala, JJ, 1989) |
| "Treatment with hydroxyurea was followed by a dramatic response of both the polycythemia vera and the HES, with return to normal of the abnormal immunologic measures." | 1.27 | Hypereosinophilic syndrome associated with polycythemia vera. ( Berrebi, A; Varon, D; Wetzler, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (17.74) | 18.7374 |
| 1990's | 13 (20.97) | 18.2507 |
| 2000's | 17 (27.42) | 29.6817 |
| 2010's | 14 (22.58) | 24.3611 |
| 2020's | 7 (11.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hassan, Z | 1 |
| Iqbal, A | 1 |
| Zahoor, S | 1 |
| Ali, I | 1 |
| Iqbal, MM | 1 |
| Bibi, R | 1 |
| Fodil, S | 1 |
| Chevret, S | 1 |
| Rouzaud, C | 1 |
| Valade, S | 1 |
| Rabian, F | 1 |
| Mariotte, E | 1 |
| Raffoux, E | 1 |
| Itzykson, R | 1 |
| Boissel, N | 1 |
| Sébert, M | 1 |
| Adès, L | 1 |
| Zafrani, L | 1 |
| Azoulay, E | 1 |
| Lengliné, E | 1 |
| Sakamoto, K | 1 |
| Kikuchi, K | 2 |
| Sako, M | 1 |
| Kato, M | 1 |
| Takimoto, T | 1 |
| Shioda, Y | 1 |
| Verma, SP | 1 |
| Kumar, N | 1 |
| Jain, M | 1 |
| Tripathi, AK | 1 |
| Ielasi, A | 1 |
| Loffi, M | 1 |
| Buono, A | 1 |
| De Blasio, G | 1 |
| Tespili, M | 1 |
| Joice, GA | 1 |
| Liu, JL | 1 |
| Burnett, AL | 1 |
| Rankine-Mullings, A | 1 |
| Reid, M | 3 |
| Soares, D | 1 |
| Taylor-Bryan, C | 1 |
| Wisdom-Phipps, M | 1 |
| Aldred, K | 1 |
| Latham, T | 1 |
| Schultz, WH | 1 |
| Knight-Madden, J | 3 |
| Badaloo, A | 1 |
| Lane, A | 1 |
| Adams, RJ | 1 |
| Ware, RE | 2 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 1 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 2 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 1 |
| Zhou, J | 1 |
| Han, J | 1 |
| Nutescu, EA | 1 |
| Gordeuk, VR | 1 |
| Saraf, SL | 1 |
| Calip, GS | 1 |
| Barbui, T | 2 |
| Finazzi, G | 2 |
| Vannucchi, AM | 2 |
| De Stefano, V | 2 |
| Rossi, E | 1 |
| Carobbio, A | 1 |
| Ghirardi, A | 1 |
| Betti, S | 1 |
| Berchie, PO | 1 |
| Sarfo, FS | 1 |
| Opare-Sem, OK | 1 |
| Ovbiagele, B | 1 |
| Abdullahi, SU | 1 |
| DeBaun, MR | 1 |
| Jordan, LC | 1 |
| Rodeghier, M | 1 |
| Galadanci, NA | 1 |
| Thol, F | 1 |
| Schlenk, RF | 1 |
| Lizarralde Palacios, E | 1 |
| Gutiérrez Macías, A | 1 |
| Rámiz Martínez, M | 1 |
| Escalante Boleas, M | 1 |
| Cunningham-Myrie, C | 1 |
| Abdulkadri, A | 1 |
| Waugh, A | 1 |
| Bortolusso Ali, S | 1 |
| King, LG | 1 |
| Minniti, CP | 1 |
| Kato, GJ | 1 |
| Diogo, CC | 1 |
| Fabretti, AK | 1 |
| Camassa, JA | 1 |
| Bonelli, Mde A | 1 |
| Arias, MV | 1 |
| Pereira, PM | 1 |
| Janot, F | 1 |
| de Raucourt, D | 1 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Bensadoun, RJ | 1 |
| Hamoir, M | 1 |
| Géry, B | 1 |
| Julieron, M | 1 |
| Castaing, M | 1 |
| Bardet, E | 1 |
| Grégoire, V | 1 |
| Bourhis, J | 1 |
| Ali, FR | 1 |
| Roberts, LN | 1 |
| Mistry, H | 1 |
| Patel, RK | 1 |
| Edmondson, RA | 1 |
| Arya, R | 1 |
| Reardon, DA | 1 |
| Egorin, MJ | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Beumer, JH | 1 |
| Lagattuta, TF | 1 |
| Gururangan, S | 1 |
| Herndon, JE | 1 |
| Salvado, AJ | 1 |
| Friedman, HS | 1 |
| Kurosawa, H | 1 |
| Okuya, M | 1 |
| Matsushita, T | 1 |
| Kubota, T | 1 |
| Endoh, K | 1 |
| Kuwashima, S | 1 |
| Hagisawa, S | 1 |
| Sato, Y | 1 |
| Fukushima, K | 1 |
| Sugita, K | 1 |
| Okada, Y | 1 |
| Park, MJ | 1 |
| Hayashi, Y | 1 |
| Arisaka, O | 1 |
| Arita, K | 1 |
| Tateishi, Y | 1 |
| Onozawa, M | 1 |
| Akiyama, M | 1 |
| Shimizu, H | 1 |
| Ali, SB | 1 |
| Moosang, M | 1 |
| King, L | 1 |
| Kim, KT | 1 |
| Sohn, SI | 1 |
| Cho, KH | 1 |
| Amrolia, PJ | 1 |
| Almeida, A | 1 |
| Davies, SC | 1 |
| Roberts, IA | 1 |
| Charlanne, H | 1 |
| Prin, L | 1 |
| Krishnamoorthy, P | 1 |
| Alyaarubi, S | 1 |
| Abish, S | 1 |
| Gale, M | 1 |
| Albuquerque, P | 1 |
| Jabado, N | 1 |
| Kako, S | 1 |
| Kanda, Y | 1 |
| Sato, T | 1 |
| Goyama, S | 1 |
| Noda, N | 1 |
| Shoda, E | 1 |
| Oshima, K | 1 |
| Inoue, M | 1 |
| Izutsu, K | 1 |
| Watanabe, T | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Fukayama, M | 1 |
| Kurokawa, M | 1 |
| Tubman, VN | 1 |
| Bennett, CM | 1 |
| Luo, HY | 1 |
| Chui, DH | 1 |
| Heeney, MM | 1 |
| Jamal, R | 1 |
| Bélisle, C | 1 |
| Lessard, MC | 1 |
| Hébert, J | 1 |
| Roy, DC | 1 |
| Levine, R | 1 |
| Busque, L | 1 |
| Mead, GM | 1 |
| Jacobs, C | 1 |
| Bauman, JL | 1 |
| Shulruff, S | 1 |
| Hasegawa, GR | 1 |
| Roden, R | 1 |
| Hartsough, N | 1 |
| Bauernfeind, RA | 1 |
| Steinberg, MH | 1 |
| Kinney, TR | 1 |
| Ring, T | 1 |
| Vaughan, WP | 1 |
| Kris, E | 1 |
| Vose, J | 1 |
| Bierman, PJ | 1 |
| Gwilt, P | 1 |
| Armitage, JO | 1 |
| Cinkotai, KI | 1 |
| Wood, P | 1 |
| Donnai, P | 1 |
| Kendra, J | 1 |
| Stehman, FB | 1 |
| Bundy, BN | 1 |
| Thomas, G | 1 |
| Keys, HM | 1 |
| d'Ablaing, G | 1 |
| Fowler, WC | 1 |
| Mortel, R | 1 |
| Creasman, WT | 1 |
| Goldman, JM | 1 |
| Szydlo, R | 1 |
| Horowitz, MM | 1 |
| Gale, RP | 1 |
| Ash, RC | 1 |
| Atkinson, K | 1 |
| Dicke, KA | 1 |
| Gluckman, E | 1 |
| Herzig, RH | 1 |
| Marmont, A | 1 |
| in 't Veld, BA | 1 |
| Slappendel, AM | 1 |
| Feenstra, J | 1 |
| Veen, C | 1 |
| van Aken, J | 1 |
| Runhaar, EA | 1 |
| Stricker, BH | 1 |
| Higashigawa, M | 1 |
| Hori, H | 1 |
| Hirayama, M | 1 |
| Kawasaki, H | 1 |
| Ido, M | 1 |
| Azuma, E | 1 |
| Sakurai, M | 1 |
| Al Jam'a, AH | 1 |
| Al Dabbous, IA | 1 |
| Grace, RF | 1 |
| Shenfield, GM | 1 |
| Grant, J | 1 |
| Ravich, R | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Ruiz-Delgado, GJ | 1 |
| Ruiz-Reyes, G | 1 |
| Chernoff, SG | 1 |
| Kaya, H | 1 |
| Gündogdu, M | 1 |
| Tekin, SB | 1 |
| Akarsu, E | 1 |
| Bozkurt, E | 1 |
| Abhyankar, D | 1 |
| Shende, C | 1 |
| Saikia, T | 1 |
| Advani, SH | 1 |
| Schmugge, M | 1 |
| Frischknecht, H | 1 |
| Yonekawa, Y | 1 |
| Baumgartner, RW | 1 |
| Boltshauser, E | 1 |
| Humbert, J | 1 |
| Gallant, C | 1 |
| Vial, T | 1 |
| Allochon, Y | 1 |
| Monier, JM | 1 |
| Blanc, M | 1 |
| Evreux, JC | 1 |
| Camba, L | 1 |
| Bernardi, M | 1 |
| Pescarollo, A | 1 |
| Slavin, S | 1 |
| Ackerstein, A | 1 |
| Morecki, S | 1 |
| Gelfand, Y | 1 |
| Cividalli, G | 1 |
| Gyan, E | 1 |
| Darre, S | 1 |
| Jude, B | 1 |
| Cambier, N | 1 |
| Demory, JL | 1 |
| Bauters, F | 1 |
| Das, R | 1 |
| Kaur, U | 1 |
| Garewal, G | 1 |
| Levin, VA | 1 |
| Wilson, CB | 1 |
| Davis, R | 1 |
| Wara, W | 1 |
| Pischer, TL | 1 |
| Irwin, L | 1 |
| Seidel, HJ | 1 |
| Opitz, U | 1 |
| Shin, KH | 1 |
| Nakagawa, H | 1 |
| Tsurufuji, S | 1 |
| Laursen, LS | 1 |
| Naesdal, J | 1 |
| Bukhave, K | 1 |
| Lauritsen, K | 1 |
| Rask-Madsen, J | 1 |
| Archimbaud, E | 1 |
| Troncy, J | 1 |
| Sebban, C | 1 |
| Guyotat, D | 1 |
| Devaux, Y | 1 |
| French, M | 1 |
| Moriceau, M | 1 |
| Viala, JJ | 1 |
| Fiere, D | 1 |
| Froom, P | 1 |
| Quitt, M | 1 |
| Aghai, E | 1 |
| Fischer, TJ | 1 |
| Daugherty, C | 1 |
| Gushurst, C | 1 |
| Kephart, GM | 1 |
| Gleich, GJ | 1 |
| Varon, D | 1 |
| Wetzler, M | 1 |
| Berrebi, A | 1 |
| Gasser, AB | 1 |
| Steward, WP | 1 |
| Wagstaff, J | 1 |
| Scarffe, JH | 1 |
| Crowther, D | 1 |
| Moschella, SL | 1 |
| Greenwald, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II[NCT02560935] | Phase 3 | 440 participants (Actual) | Interventional | 2016-07-19 | Completed | ||
| Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa[NCT02675790] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Completed | ||
| Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea[NCT00387933] | Phase 1 | 37 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxyurea and Recrudescence
| Article | Year |
|---|---|
Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.
Topics: Adult; Antineoplastic Agents; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Male; | 2020 |
Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Algori | 2021 |
Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2014 |
[Fever induced by hydroxycarbamide].
Topics: Aged; Fever; Humans; Hydroxyurea; Male; Myalgia; Recurrence; Thrombocythemia, Essential | 2015 |
Critical Reviews: How we treat sickle cell patients with leg ulcers.
Topics: Anemia, Sickle Cell; Drug Therapy, Combination; Erythropoietin; Humans; Hydroxyurea; Leg Ulcer; Recu | 2016 |
Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Central Nervous System Diseas | 2003 |
[Treatment of hypereosinophilia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzam | 2006 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
9 trials available for hydroxyurea and Recrudescence
| Article | Year |
|---|---|
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2021 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Gl | 2009 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Cause of Death; Chemotherapy, Adjuvant; Female; Follow-Up | 1993 |
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
Topics: Actuarial Analysis; Bone Marrow Transplantation; Busulfan; Follow-Up Studies; Humans; Hydroxyurea; L | 1993 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; E | 1985 |
45 other studies available for hydroxyurea and Recrudescence
| Article | Year |
|---|---|
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients.
Topics: Aged; Cost-Benefit Analysis; Developing Countries; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, | 2022 |
Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.
Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Proportional Hazards Models; Recurrence; Remission In | 2022 |
Pilot study to estimate the safety and effectiveness of hydroxyurea and methotrexate recurrent langerhans cell histiocytosis (LCH-HU-pilot).
Topics: Histiocytosis, Langerhans-Cell; Humans; Hydroxyurea; Methotrexate; Pilot Projects; Recurrence | 2022 |
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting St | 2020 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Antisickling Agents; Child; Child, P | 2018 |
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.
Topics: Humans; Hydroxyurea; Leukocyte Count; Myeloid Cells; Myeloproliferative Disorders; Recurrence; Strok | 2018 |
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Myeloprol | 2018 |
Recurrent Stroke in a Ghanaian Patient With Polycythemia.
Topics: Aphasia, Broca; Aspirin; Clopidogrel; Ghana; Humans; Hydroxyurea; Infarction, Middle Cerebral Artery | 2019 |
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cost-Benefit Analysis; Developing Countries; Female | 2015 |
Diagnosis and Treatment of Primary Erythrocytosis in a Dog: A Case Report.
Topics: Animals; Antineoplastic Agents; Diagnosis, Differential; Dog Diseases; Dogs; Euthanasia, Animal; Fat | 2015 |
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Topics: Anticoagulants; Arterial Occlusive Diseases; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; | 2009 |
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu | 2009 |
Recurrence of hydroxyurea-induced leg ulcer after discontinuation of treatment.
Topics: Aged, 80 and over; Biopsy; Humans; Hydroxyurea; Leg Ulcer; Male; Polycythemia Vera; Recurrence; Trea | 2011 |
Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; Female; Humans; Hydroxyurea; Male; Recurrence; Stroke | 2011 |
Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Biopsy; Bone Marrow Examination; Cerebral Angiography; Cerebral Infarct | 2012 |
Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
Topics: Adenoma; Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Arthralgia; Back Pain; Bone Resorption | 2006 |
Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotide | 2007 |
Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.
Topics: Abdominal Pain; Acute Disease; Anemia, Sickle Cell; Cholecystectomy; Cholecystitis; Exchange Transfu | 2007 |
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.
Topics: Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Janus Kinase 2; Leukemi | 2008 |
Fever caused by hydroxyurea.
Topics: Aspirin; Female; Fever; Humans; Hydroxyurea; Middle Aged; Psoriasis; Recurrence | 1981 |
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Blood Group Incompatibility; Blood Transfusion; Cerebrovascular Disorder | 1995 |
Hydroxyurea in essential thrombocytosis.
Topics: Data Interpretation, Statistical; Humans; Hydroxyurea; Multivariate Analysis; Recurrence; Thrombocyt | 1995 |
Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion.
Topics: Abortion, Habitual; Adult; Blood Platelets; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Compli | 1994 |
Fever attributed to the use of hydroxyurea.
Topics: Aged; Antineoplastic Agents; Female; Fever; Humans; Hydroxyurea; Male; Recurrence; Thrombocytosis | 1997 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Co | 1997 |
Hydroxyurea in the treatment of sickle cell associated priapism.
Topics: Adult; Antisickling Agents; Humans; Hydroxyurea; Male; Priapism; Recurrence; Sickle Cell Trait | 1998 |
Recurrent pyrexia, cough and dyspnoea with hydroxyurea.
Topics: Cough; Dyspnea; Fever; Humans; Hydroxyurea; Male; Middle Aged; Polycythemia Vera; Recurrence | 1998 |
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet A | 1998 |
Essential thrombocythemia and recurrent myocardial infarction.
Topics: Angina, Unstable; Female; Humans; Hydroxyurea; Middle Aged; Myocardial Infarction; Platelet Count; R | 2000 |
Hydroxyurea induced leg ulcers.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2000 |
Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery.
Topics: Anemia, Sickle Cell; Aphasia; Blood Flow Velocity; Blood Transfusion; Brain Damage, Chronic; Brain I | 2001 |
[Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases].
Topics: Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Fever; Humans; Hydroxyurea; Male; Middle Age | 1998 |
Complete haematological response with granulocyte colony stimulating factor (G-CSF) and hydroxyurea in relapsed acute myeloid leukaemia (AML) of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Granulocyte Colony-Stimulating Factor; Humans; | 2001 |
Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Child; Combined Modality Therapy; Fe | 2001 |
Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Cell Adhesion; Erythrocyte Membrane; Etilefri | 2001 |
Splenectomy in a case of splenic vein thrombosis unmasks essential thrombocythemia.
Topics: Adult; Hematemesis; Humans; Hydroxyurea; Hypertension, Portal; Ischemic Attack, Transient; Male; Pla | 2002 |
Hematopoietic stem cells in Friend murine leukemia virus-infected mice undergoing chemotherapy: remission and relapse of erythropoietin-independent erythropoiesis induced by hydroxyurea.
Topics: Animals; Cell Survival; Colony-Forming Units Assay; Erythropoiesis; Erythropoietin; Female; Friend m | 1979 |
Inhibition by hydroxyurea of the rebound of granulomatous inflammation following withdrawal of glucocorticoid therapy.
Topics: Animals; DNA; Granuloma; Hydrocortisone; Hydroxyurea; Male; Rats; Recurrence; Time Factors | 1975 |
Selective 5-lipoxygenase inhibition in ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonate Lipoxygenases; Colitis, Ulcerativ | 1990 |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia.
Topics: Bone Marrow; Drug Evaluation; Drug Resistance; Drug Synergism; Humans; Hydroxyurea; Leukemia, Myeloi | 1989 |
The mean leukocyte myeloperoxidase index in hematological patients.
Topics: Hematologic Diseases; Hospitalization; Humans; Hydroxyurea; Leukocytes; Lymphoma; Lymphoma, Non-Hodg | 1989 |
Systemic vasculitis associated with eosinophilia and marked degranulation of tissue eosinophils.
Topics: Blood Proteins; Child; Diagnosis, Differential; Eosinophil Granule Proteins; Eosinophilia; Eosinophi | 1988 |
Hypereosinophilic syndrome associated with polycythemia vera.
Topics: Eosinophilia; Female; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Re | 1986 |
Psoriasis with hydroxyurea. An 18-month study of 60 patients.
Topics: Adult; Aged; Anemia; Chemical and Drug Induced Liver Injury; Drug Resistance; Female; Humans; Hydrox | 1973 |